Global Azacitidine Drug
Global Azacitidine Drug

Azacitidine Drug Comprehensive Study by Type (Acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS)), Application (Refractory anemia (RA), Refractory anemia with excess blasts (RAEB), Chronic myelomonocytic leukemia (CMMoL), Others), Route of Administration (Oral, Injection), Distribution Channel (Online, Offline), Dose (100 mg, 200 mg, 300 mg, Others), End User (Hospital, Home Care Settings, Elderly Care Facilities, Others) Players and Region - Global Market Outlook to 2026

Azacitidine Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 225 Pages 174 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Azacitidine Drug?
Azacitadine is a cytotoxic chemotherapy drug. This medication is classified as an antimetobolite and a demethylating agent. This medication is used to treat a group of blood/bone marrow disorders (myelodysplastic syndromes-MDS) in which the bone marrow does not produce enough healthy blood cells. People with MDS usually have problems such as infections, anemia, and easy bleeding/bruising. Azacitidine is a chemotherapy drug.

The market study is broken down by Type (Acute myeloid leukemia (AML) and Myelodysplastic syndrome (MDS)), by Application (Refractory anemia (RA), Refractory anemia with excess blasts (RAEB), Chronic myelomonocytic leukemia (CMMoL) and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that Players from United States will contribute to the maximum growth of Global Azacitidine Drug market throughout the predicted period.

Celgene (United States), Mylan N.V. (United States), Shilpa Medicare (United States), Pfizer Inc. (United States), Teva Pharmaceuticals (Israel), Sandoz (Germany), Sanofi (France), GlaxoSmithKline (United Kingdom), Novartis (Switzerland) and Dr. Reddy's Laboratories (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sun Pharmaceutical Industries Ltd. (India), Natco Pharma (India) and Accord Healthcare (India).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Azacitidine Drug market by Type, Application and Region.

On the basis of geography, the market of Azacitidine Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Azacitidine Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Azacitidine Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dose, the sub-segment i.e. 100 mg will boost the Azacitidine Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital will boost the Azacitidine Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

On 1st September 2020, the Food and Drug Administration approved azacitidine tablets (ONUREG, Celgene Corporation) for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.


Market Trend
  • Rising Research and Development Activities to Develop Azacitidine Drug

Market Drivers
  • Increasing Number of the Population with the Myelodysplastic Syndromes (MDS) Disorder
  • Growing Pharmaceuticals Industry across the Globe

Opportunities
  • Increasing Demand From Developing Nations

Restraints
  • Various Side Effects Like Low Blood Counts

Challenges
  • Strict Norms and Regulations


Key Target Audience
Azacitidine Drug panel Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

About Approach
During this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Acute myeloid leukemia (AML)
  • Myelodysplastic syndrome (MDS)
By Application
  • Refractory anemia (RA)
  • Refractory anemia with excess blasts (RAEB)
  • Chronic myelomonocytic leukemia (CMMoL)
  • Others
By Route of Administration
  • Oral
  • Injection

By Distribution Channel
  • Online
  • Offline

By Dose
  • 100 mg
  • 200 mg
  • 300 mg
  • Others

By End User
  • Hospital
  • Home Care Settings
  • Elderly Care Facilities
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of the Population with the Myelodysplastic Syndromes (MDS) Disorder
      • 3.2.2. Growing Pharmaceuticals Industry across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Strict Norms and Regulations
    • 3.4. Market Trends
      • 3.4.1. Rising Research and Development Activities to Develop Azacitidine Drug
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Azacitidine Drug, by Type, Application, Route of Administration, Distribution Channel, Dose, End User and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Azacitidine Drug (Value)
      • 5.2.1. Global Azacitidine Drug by: Type (Value)
        • 5.2.1.1. Acute myeloid leukemia (AML)
        • 5.2.1.2. Myelodysplastic syndrome (MDS)
      • 5.2.2. Global Azacitidine Drug by: Application (Value)
        • 5.2.2.1. Refractory anemia (RA)
        • 5.2.2.2. Refractory anemia with excess blasts (RAEB)
        • 5.2.2.3. Chronic myelomonocytic leukemia (CMMoL)
        • 5.2.2.4. Others
      • 5.2.3. Global Azacitidine Drug by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injection
      • 5.2.4. Global Azacitidine Drug by: Distribution Channel (Value)
        • 5.2.4.1. Online
        • 5.2.4.2. Offline
      • 5.2.5. Global Azacitidine Drug by: Dose (Value)
        • 5.2.5.1. 100 mg
        • 5.2.5.2. 200 mg
        • 5.2.5.3. 300 mg
        • 5.2.5.4. Others
      • 5.2.6. Global Azacitidine Drug by: End User (Value)
        • 5.2.6.1. Hospital
        • 5.2.6.2. Home Care Settings
        • 5.2.6.3. Elderly Care Facilities
        • 5.2.6.4. Others
      • 5.2.7. Global Azacitidine Drug Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Azacitidine Drug (Volume)
      • 5.3.1. Global Azacitidine Drug by: Type (Volume)
        • 5.3.1.1. Acute myeloid leukemia (AML)
        • 5.3.1.2. Myelodysplastic syndrome (MDS)
      • 5.3.2. Global Azacitidine Drug by: Application (Volume)
        • 5.3.2.1. Refractory anemia (RA)
        • 5.3.2.2. Refractory anemia with excess blasts (RAEB)
        • 5.3.2.3. Chronic myelomonocytic leukemia (CMMoL)
        • 5.3.2.4. Others
      • 5.3.3. Global Azacitidine Drug by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Injection
      • 5.3.4. Global Azacitidine Drug by: Distribution Channel (Volume)
        • 5.3.4.1. Online
        • 5.3.4.2. Offline
      • 5.3.5. Global Azacitidine Drug by: Dose (Volume)
        • 5.3.5.1. 100 mg
        • 5.3.5.2. 200 mg
        • 5.3.5.3. 300 mg
        • 5.3.5.4. Others
      • 5.3.6. Global Azacitidine Drug by: End User (Volume)
        • 5.3.6.1. Hospital
        • 5.3.6.2. Home Care Settings
        • 5.3.6.3. Elderly Care Facilities
        • 5.3.6.4. Others
      • 5.3.7. Global Azacitidine Drug Region
        • 5.3.7.1. South America
          • 5.3.7.1.1. Brazil
          • 5.3.7.1.2. Argentina
          • 5.3.7.1.3. Rest of South America
        • 5.3.7.2. Asia Pacific
          • 5.3.7.2.1. China
          • 5.3.7.2.2. Japan
          • 5.3.7.2.3. India
          • 5.3.7.2.4. South Korea
          • 5.3.7.2.5. Taiwan
          • 5.3.7.2.6. Australia
          • 5.3.7.2.7. Rest of Asia-Pacific
        • 5.3.7.3. Europe
          • 5.3.7.3.1. Germany
          • 5.3.7.3.2. France
          • 5.3.7.3.3. Italy
          • 5.3.7.3.4. United Kingdom
          • 5.3.7.3.5. Netherlands
          • 5.3.7.3.6. Rest of Europe
        • 5.3.7.4. MEA
          • 5.3.7.4.1. Middle East
          • 5.3.7.4.2. Africa
        • 5.3.7.5. North America
          • 5.3.7.5.1. United States
          • 5.3.7.5.2. Canada
          • 5.3.7.5.3. Mexico
    • 5.4. Global Azacitidine Drug (Price)
      • 5.4.1. Global Azacitidine Drug by: Type (Price)
  • 6. Azacitidine Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Celgene (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mylan N.V. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Shilpa Medicare (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Teva Pharmaceuticals (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sandoz (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Dr. Reddy's Laboratories (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Azacitidine Drug Sale, by Type, Application, Route of Administration, Distribution Channel, Dose, End User and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Azacitidine Drug (Value)
      • 7.2.1. Global Azacitidine Drug by: Type (Value)
        • 7.2.1.1. Acute myeloid leukemia (AML)
        • 7.2.1.2. Myelodysplastic syndrome (MDS)
      • 7.2.2. Global Azacitidine Drug by: Application (Value)
        • 7.2.2.1. Refractory anemia (RA)
        • 7.2.2.2. Refractory anemia with excess blasts (RAEB)
        • 7.2.2.3. Chronic myelomonocytic leukemia (CMMoL)
        • 7.2.2.4. Others
      • 7.2.3. Global Azacitidine Drug by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injection
      • 7.2.4. Global Azacitidine Drug by: Distribution Channel (Value)
        • 7.2.4.1. Online
        • 7.2.4.2. Offline
      • 7.2.5. Global Azacitidine Drug by: Dose (Value)
        • 7.2.5.1. 100 mg
        • 7.2.5.2. 200 mg
        • 7.2.5.3. 300 mg
        • 7.2.5.4. Others
      • 7.2.6. Global Azacitidine Drug by: End User (Value)
        • 7.2.6.1. Hospital
        • 7.2.6.2. Home Care Settings
        • 7.2.6.3. Elderly Care Facilities
        • 7.2.6.4. Others
      • 7.2.7. Global Azacitidine Drug Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Azacitidine Drug (Volume)
      • 7.3.1. Global Azacitidine Drug by: Type (Volume)
        • 7.3.1.1. Acute myeloid leukemia (AML)
        • 7.3.1.2. Myelodysplastic syndrome (MDS)
      • 7.3.2. Global Azacitidine Drug by: Application (Volume)
        • 7.3.2.1. Refractory anemia (RA)
        • 7.3.2.2. Refractory anemia with excess blasts (RAEB)
        • 7.3.2.3. Chronic myelomonocytic leukemia (CMMoL)
        • 7.3.2.4. Others
      • 7.3.3. Global Azacitidine Drug by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Injection
      • 7.3.4. Global Azacitidine Drug by: Distribution Channel (Volume)
        • 7.3.4.1. Online
        • 7.3.4.2. Offline
      • 7.3.5. Global Azacitidine Drug by: Dose (Volume)
        • 7.3.5.1. 100 mg
        • 7.3.5.2. 200 mg
        • 7.3.5.3. 300 mg
        • 7.3.5.4. Others
      • 7.3.6. Global Azacitidine Drug by: End User (Volume)
        • 7.3.6.1. Hospital
        • 7.3.6.2. Home Care Settings
        • 7.3.6.3. Elderly Care Facilities
        • 7.3.6.4. Others
      • 7.3.7. Global Azacitidine Drug Region
        • 7.3.7.1. South America
          • 7.3.7.1.1. Brazil
          • 7.3.7.1.2. Argentina
          • 7.3.7.1.3. Rest of South America
        • 7.3.7.2. Asia Pacific
          • 7.3.7.2.1. China
          • 7.3.7.2.2. Japan
          • 7.3.7.2.3. India
          • 7.3.7.2.4. South Korea
          • 7.3.7.2.5. Taiwan
          • 7.3.7.2.6. Australia
          • 7.3.7.2.7. Rest of Asia-Pacific
        • 7.3.7.3. Europe
          • 7.3.7.3.1. Germany
          • 7.3.7.3.2. France
          • 7.3.7.3.3. Italy
          • 7.3.7.3.4. United Kingdom
          • 7.3.7.3.5. Netherlands
          • 7.3.7.3.6. Rest of Europe
        • 7.3.7.4. MEA
          • 7.3.7.4.1. Middle East
          • 7.3.7.4.2. Africa
        • 7.3.7.5. North America
          • 7.3.7.5.1. United States
          • 7.3.7.5.2. Canada
          • 7.3.7.5.3. Mexico
    • 7.4. Global Azacitidine Drug (Price)
      • 7.4.1. Global Azacitidine Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Azacitidine Drug: by Type(USD Million)
  • Table 2. Azacitidine Drug Acute myeloid leukemia (AML) , by Region USD Million (2015-2020)
  • Table 3. Azacitidine Drug Myelodysplastic syndrome (MDS) , by Region USD Million (2015-2020)
  • Table 4. Azacitidine Drug: by Application(USD Million)
  • Table 5. Azacitidine Drug Refractory anemia (RA) , by Region USD Million (2015-2020)
  • Table 6. Azacitidine Drug Refractory anemia with excess blasts (RAEB) , by Region USD Million (2015-2020)
  • Table 7. Azacitidine Drug Chronic myelomonocytic leukemia (CMMoL) , by Region USD Million (2015-2020)
  • Table 8. Azacitidine Drug Others , by Region USD Million (2015-2020)
  • Table 9. Azacitidine Drug: by Route of Administration(USD Million)
  • Table 10. Azacitidine Drug Oral , by Region USD Million (2015-2020)
  • Table 11. Azacitidine Drug Injection , by Region USD Million (2015-2020)
  • Table 12. Azacitidine Drug: by Distribution Channel(USD Million)
  • Table 13. Azacitidine Drug Online , by Region USD Million (2015-2020)
  • Table 14. Azacitidine Drug Offline , by Region USD Million (2015-2020)
  • Table 15. Azacitidine Drug: by Dose(USD Million)
  • Table 16. Azacitidine Drug 100 mg , by Region USD Million (2015-2020)
  • Table 17. Azacitidine Drug 200 mg , by Region USD Million (2015-2020)
  • Table 18. Azacitidine Drug 300 mg , by Region USD Million (2015-2020)
  • Table 19. Azacitidine Drug Others , by Region USD Million (2015-2020)
  • Table 20. Azacitidine Drug: by End User(USD Million)
  • Table 21. Azacitidine Drug Hospital , by Region USD Million (2015-2020)
  • Table 22. Azacitidine Drug Home Care Settings , by Region USD Million (2015-2020)
  • Table 23. Azacitidine Drug Elderly Care Facilities , by Region USD Million (2015-2020)
  • Table 24. Azacitidine Drug Others , by Region USD Million (2015-2020)
  • Table 25. South America Azacitidine Drug, by Country USD Million (2015-2020)
  • Table 26. South America Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 27. South America Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 28. South America Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 29. South America Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 30. South America Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 31. South America Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 32. Brazil Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 33. Brazil Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 34. Brazil Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 35. Brazil Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 36. Brazil Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 37. Brazil Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 38. Argentina Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 39. Argentina Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 40. Argentina Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 41. Argentina Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 42. Argentina Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 43. Argentina Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 44. Rest of South America Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 45. Rest of South America Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 46. Rest of South America Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 47. Rest of South America Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 48. Rest of South America Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 49. Rest of South America Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 50. Asia Pacific Azacitidine Drug, by Country USD Million (2015-2020)
  • Table 51. Asia Pacific Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 52. Asia Pacific Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 53. Asia Pacific Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 54. Asia Pacific Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 55. Asia Pacific Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 56. Asia Pacific Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 57. China Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 58. China Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 59. China Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 60. China Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 61. China Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 62. China Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 63. Japan Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 64. Japan Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 65. Japan Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 66. Japan Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 67. Japan Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 68. Japan Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 69. India Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 70. India Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 71. India Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 72. India Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 73. India Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 74. India Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 75. South Korea Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 76. South Korea Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 77. South Korea Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 78. South Korea Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 79. South Korea Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 80. South Korea Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 81. Taiwan Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 82. Taiwan Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 83. Taiwan Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 84. Taiwan Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 85. Taiwan Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 86. Taiwan Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 87. Australia Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 88. Australia Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 89. Australia Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 90. Australia Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 91. Australia Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 92. Australia Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 93. Rest of Asia-Pacific Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 94. Rest of Asia-Pacific Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 95. Rest of Asia-Pacific Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 96. Rest of Asia-Pacific Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 97. Rest of Asia-Pacific Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 98. Rest of Asia-Pacific Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 99. Europe Azacitidine Drug, by Country USD Million (2015-2020)
  • Table 100. Europe Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 101. Europe Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 102. Europe Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 103. Europe Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 104. Europe Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 105. Europe Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 106. Germany Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 107. Germany Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 108. Germany Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 109. Germany Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 110. Germany Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 111. Germany Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 112. France Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 113. France Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 114. France Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 115. France Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 116. France Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 117. France Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 118. Italy Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 119. Italy Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 120. Italy Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 121. Italy Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 122. Italy Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 123. Italy Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 124. United Kingdom Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 125. United Kingdom Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 126. United Kingdom Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 127. United Kingdom Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 128. United Kingdom Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 129. United Kingdom Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 130. Netherlands Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 131. Netherlands Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 132. Netherlands Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 133. Netherlands Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 134. Netherlands Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 135. Netherlands Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 136. Rest of Europe Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 137. Rest of Europe Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 138. Rest of Europe Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 139. Rest of Europe Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 140. Rest of Europe Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 141. Rest of Europe Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 142. MEA Azacitidine Drug, by Country USD Million (2015-2020)
  • Table 143. MEA Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 144. MEA Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 145. MEA Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 146. MEA Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 147. MEA Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 148. MEA Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 149. Middle East Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 150. Middle East Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 151. Middle East Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 152. Middle East Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 153. Middle East Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 154. Middle East Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 155. Africa Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 156. Africa Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 157. Africa Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 158. Africa Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 159. Africa Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 160. Africa Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 161. North America Azacitidine Drug, by Country USD Million (2015-2020)
  • Table 162. North America Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 163. North America Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 164. North America Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 165. North America Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 166. North America Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 167. North America Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 168. United States Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 169. United States Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 170. United States Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 171. United States Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 172. United States Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 173. United States Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 174. Canada Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 175. Canada Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 176. Canada Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 177. Canada Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 178. Canada Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 179. Canada Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 180. Mexico Azacitidine Drug, by Type USD Million (2015-2020)
  • Table 181. Mexico Azacitidine Drug, by Application USD Million (2015-2020)
  • Table 182. Mexico Azacitidine Drug, by Route of Administration USD Million (2015-2020)
  • Table 183. Mexico Azacitidine Drug, by Distribution Channel USD Million (2015-2020)
  • Table 184. Mexico Azacitidine Drug, by Dose USD Million (2015-2020)
  • Table 185. Mexico Azacitidine Drug, by End User USD Million (2015-2020)
  • Table 186. Azacitidine Drug Sales: by Type(Tonne)
  • Table 187. Azacitidine Drug Sales Acute myeloid leukemia (AML) , by Region Tonne (2015-2020)
  • Table 188. Azacitidine Drug Sales Myelodysplastic syndrome (MDS) , by Region Tonne (2015-2020)
  • Table 189. Azacitidine Drug Sales: by Application(Tonne)
  • Table 190. Azacitidine Drug Sales Refractory anemia (RA) , by Region Tonne (2015-2020)
  • Table 191. Azacitidine Drug Sales Refractory anemia with excess blasts (RAEB) , by Region Tonne (2015-2020)
  • Table 192. Azacitidine Drug Sales Chronic myelomonocytic leukemia (CMMoL) , by Region Tonne (2015-2020)
  • Table 193. Azacitidine Drug Sales Others , by Region Tonne (2015-2020)
  • Table 194. Azacitidine Drug Sales: by Route of Administration(Tonne)
  • Table 195. Azacitidine Drug Sales Oral , by Region Tonne (2015-2020)
  • Table 196. Azacitidine Drug Sales Injection , by Region Tonne (2015-2020)
  • Table 197. Azacitidine Drug Sales: by Distribution Channel(Tonne)
  • Table 198. Azacitidine Drug Sales Online , by Region Tonne (2015-2020)
  • Table 199. Azacitidine Drug Sales Offline , by Region Tonne (2015-2020)
  • Table 200. Azacitidine Drug Sales: by Dose(Tonne)
  • Table 201. Azacitidine Drug Sales 100 mg , by Region Tonne (2015-2020)
  • Table 202. Azacitidine Drug Sales 200 mg , by Region Tonne (2015-2020)
  • Table 203. Azacitidine Drug Sales 300 mg , by Region Tonne (2015-2020)
  • Table 204. Azacitidine Drug Sales Others , by Region Tonne (2015-2020)
  • Table 205. Azacitidine Drug Sales: by End User(Tonne)
  • Table 206. Azacitidine Drug Sales Hospital , by Region Tonne (2015-2020)
  • Table 207. Azacitidine Drug Sales Home Care Settings , by Region Tonne (2015-2020)
  • Table 208. Azacitidine Drug Sales Elderly Care Facilities , by Region Tonne (2015-2020)
  • Table 209. Azacitidine Drug Sales Others , by Region Tonne (2015-2020)
  • Table 210. South America Azacitidine Drug Sales, by Country Tonne (2015-2020)
  • Table 211. South America Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 212. South America Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 213. South America Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 214. South America Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 215. South America Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 216. South America Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 217. Brazil Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 218. Brazil Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 219. Brazil Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 220. Brazil Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 221. Brazil Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 222. Brazil Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 223. Argentina Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 224. Argentina Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 225. Argentina Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 226. Argentina Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 227. Argentina Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 228. Argentina Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 229. Rest of South America Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 230. Rest of South America Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 231. Rest of South America Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 232. Rest of South America Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 233. Rest of South America Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 234. Rest of South America Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 235. Asia Pacific Azacitidine Drug Sales, by Country Tonne (2015-2020)
  • Table 236. Asia Pacific Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 237. Asia Pacific Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 238. Asia Pacific Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 239. Asia Pacific Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 240. Asia Pacific Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 241. Asia Pacific Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 242. China Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 243. China Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 244. China Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 245. China Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 246. China Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 247. China Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 248. Japan Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 249. Japan Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 250. Japan Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 251. Japan Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 252. Japan Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 253. Japan Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 254. India Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 255. India Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 256. India Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 257. India Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 258. India Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 259. India Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 260. South Korea Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 261. South Korea Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 262. South Korea Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 263. South Korea Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 264. South Korea Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 265. South Korea Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 266. Taiwan Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 267. Taiwan Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 268. Taiwan Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 269. Taiwan Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 270. Taiwan Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 271. Taiwan Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 272. Australia Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 273. Australia Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 274. Australia Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 275. Australia Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 276. Australia Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 277. Australia Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 278. Rest of Asia-Pacific Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 279. Rest of Asia-Pacific Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 280. Rest of Asia-Pacific Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 281. Rest of Asia-Pacific Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 282. Rest of Asia-Pacific Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 283. Rest of Asia-Pacific Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 284. Europe Azacitidine Drug Sales, by Country Tonne (2015-2020)
  • Table 285. Europe Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 286. Europe Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 287. Europe Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 288. Europe Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 289. Europe Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 290. Europe Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 291. Germany Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 292. Germany Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 293. Germany Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 294. Germany Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 295. Germany Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 296. Germany Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 297. France Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 298. France Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 299. France Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 300. France Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 301. France Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 302. France Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 303. Italy Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 304. Italy Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 305. Italy Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 306. Italy Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 307. Italy Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 308. Italy Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 309. United Kingdom Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 310. United Kingdom Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 311. United Kingdom Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 312. United Kingdom Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 313. United Kingdom Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 314. United Kingdom Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 315. Netherlands Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 316. Netherlands Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 317. Netherlands Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 318. Netherlands Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 319. Netherlands Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 320. Netherlands Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 321. Rest of Europe Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 322. Rest of Europe Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 323. Rest of Europe Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 324. Rest of Europe Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 325. Rest of Europe Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 326. Rest of Europe Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 327. MEA Azacitidine Drug Sales, by Country Tonne (2015-2020)
  • Table 328. MEA Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 329. MEA Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 330. MEA Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 331. MEA Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 332. MEA Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 333. MEA Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 334. Middle East Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 335. Middle East Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 336. Middle East Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 337. Middle East Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 338. Middle East Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 339. Middle East Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 340. Africa Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 341. Africa Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 342. Africa Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 343. Africa Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 344. Africa Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 345. Africa Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 346. North America Azacitidine Drug Sales, by Country Tonne (2015-2020)
  • Table 347. North America Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 348. North America Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 349. North America Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 350. North America Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 351. North America Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 352. North America Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 353. United States Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 354. United States Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 355. United States Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 356. United States Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 357. United States Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 358. United States Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 359. Canada Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 360. Canada Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 361. Canada Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 362. Canada Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 363. Canada Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 364. Canada Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 365. Mexico Azacitidine Drug Sales, by Type Tonne (2015-2020)
  • Table 366. Mexico Azacitidine Drug Sales, by Application Tonne (2015-2020)
  • Table 367. Mexico Azacitidine Drug Sales, by Route of Administration Tonne (2015-2020)
  • Table 368. Mexico Azacitidine Drug Sales, by Distribution Channel Tonne (2015-2020)
  • Table 369. Mexico Azacitidine Drug Sales, by Dose Tonne (2015-2020)
  • Table 370. Mexico Azacitidine Drug Sales, by End User Tonne (2015-2020)
  • Table 371. Azacitidine Drug: by Type(USD/Units)
  • Table 372. Company Basic Information, Sales Area and Its Competitors
  • Table 373. Company Basic Information, Sales Area and Its Competitors
  • Table 374. Company Basic Information, Sales Area and Its Competitors
  • Table 375. Company Basic Information, Sales Area and Its Competitors
  • Table 376. Company Basic Information, Sales Area and Its Competitors
  • Table 377. Company Basic Information, Sales Area and Its Competitors
  • Table 378. Company Basic Information, Sales Area and Its Competitors
  • Table 379. Company Basic Information, Sales Area and Its Competitors
  • Table 380. Company Basic Information, Sales Area and Its Competitors
  • Table 381. Company Basic Information, Sales Area and Its Competitors
  • Table 382. Azacitidine Drug: by Type(USD Million)
  • Table 383. Azacitidine Drug Acute myeloid leukemia (AML) , by Region USD Million (2021-2026)
  • Table 384. Azacitidine Drug Myelodysplastic syndrome (MDS) , by Region USD Million (2021-2026)
  • Table 385. Azacitidine Drug: by Application(USD Million)
  • Table 386. Azacitidine Drug Refractory anemia (RA) , by Region USD Million (2021-2026)
  • Table 387. Azacitidine Drug Refractory anemia with excess blasts (RAEB) , by Region USD Million (2021-2026)
  • Table 388. Azacitidine Drug Chronic myelomonocytic leukemia (CMMoL) , by Region USD Million (2021-2026)
  • Table 389. Azacitidine Drug Others , by Region USD Million (2021-2026)
  • Table 390. Azacitidine Drug: by Route of Administration(USD Million)
  • Table 391. Azacitidine Drug Oral , by Region USD Million (2021-2026)
  • Table 392. Azacitidine Drug Injection , by Region USD Million (2021-2026)
  • Table 393. Azacitidine Drug: by Distribution Channel(USD Million)
  • Table 394. Azacitidine Drug Online , by Region USD Million (2021-2026)
  • Table 395. Azacitidine Drug Offline , by Region USD Million (2021-2026)
  • Table 396. Azacitidine Drug: by Dose(USD Million)
  • Table 397. Azacitidine Drug 100 mg , by Region USD Million (2021-2026)
  • Table 398. Azacitidine Drug 200 mg , by Region USD Million (2021-2026)
  • Table 399. Azacitidine Drug 300 mg , by Region USD Million (2021-2026)
  • Table 400. Azacitidine Drug Others , by Region USD Million (2021-2026)
  • Table 401. Azacitidine Drug: by End User(USD Million)
  • Table 402. Azacitidine Drug Hospital , by Region USD Million (2021-2026)
  • Table 403. Azacitidine Drug Home Care Settings , by Region USD Million (2021-2026)
  • Table 404. Azacitidine Drug Elderly Care Facilities , by Region USD Million (2021-2026)
  • Table 405. Azacitidine Drug Others , by Region USD Million (2021-2026)
  • Table 406. South America Azacitidine Drug, by Country USD Million (2021-2026)
  • Table 407. South America Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 408. South America Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 409. South America Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 410. South America Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 411. South America Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 412. South America Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 413. Brazil Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 414. Brazil Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 415. Brazil Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 416. Brazil Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 417. Brazil Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 418. Brazil Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 419. Argentina Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 420. Argentina Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 421. Argentina Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 422. Argentina Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 423. Argentina Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 424. Argentina Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 425. Rest of South America Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 426. Rest of South America Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 427. Rest of South America Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 428. Rest of South America Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 429. Rest of South America Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 430. Rest of South America Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 431. Asia Pacific Azacitidine Drug, by Country USD Million (2021-2026)
  • Table 432. Asia Pacific Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 433. Asia Pacific Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 434. Asia Pacific Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 435. Asia Pacific Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 436. Asia Pacific Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 437. Asia Pacific Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 438. China Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 439. China Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 440. China Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 441. China Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 442. China Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 443. China Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 444. Japan Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 445. Japan Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 446. Japan Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 447. Japan Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 448. Japan Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 449. Japan Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 450. India Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 451. India Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 452. India Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 453. India Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 454. India Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 455. India Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 456. South Korea Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 457. South Korea Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 458. South Korea Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 459. South Korea Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 460. South Korea Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 461. South Korea Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 462. Taiwan Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 463. Taiwan Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 464. Taiwan Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 465. Taiwan Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 466. Taiwan Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 467. Taiwan Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 468. Australia Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 469. Australia Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 470. Australia Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 471. Australia Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 472. Australia Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 473. Australia Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 474. Rest of Asia-Pacific Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 475. Rest of Asia-Pacific Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 476. Rest of Asia-Pacific Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 477. Rest of Asia-Pacific Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 478. Rest of Asia-Pacific Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 479. Rest of Asia-Pacific Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 480. Europe Azacitidine Drug, by Country USD Million (2021-2026)
  • Table 481. Europe Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 482. Europe Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 483. Europe Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 484. Europe Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 485. Europe Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 486. Europe Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 487. Germany Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 488. Germany Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 489. Germany Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 490. Germany Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 491. Germany Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 492. Germany Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 493. France Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 494. France Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 495. France Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 496. France Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 497. France Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 498. France Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 499. Italy Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 500. Italy Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 501. Italy Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 502. Italy Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 503. Italy Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 504. Italy Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 505. United Kingdom Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 506. United Kingdom Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 507. United Kingdom Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 508. United Kingdom Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 509. United Kingdom Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 510. United Kingdom Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 511. Netherlands Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 512. Netherlands Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 513. Netherlands Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 514. Netherlands Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 515. Netherlands Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 516. Netherlands Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 517. Rest of Europe Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 518. Rest of Europe Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 519. Rest of Europe Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 520. Rest of Europe Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 521. Rest of Europe Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 522. Rest of Europe Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 523. MEA Azacitidine Drug, by Country USD Million (2021-2026)
  • Table 524. MEA Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 525. MEA Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 526. MEA Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 527. MEA Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 528. MEA Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 529. MEA Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 530. Middle East Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 531. Middle East Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 532. Middle East Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 533. Middle East Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 534. Middle East Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 535. Middle East Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 536. Africa Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 537. Africa Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 538. Africa Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 539. Africa Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 540. Africa Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 541. Africa Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 542. North America Azacitidine Drug, by Country USD Million (2021-2026)
  • Table 543. North America Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 544. North America Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 545. North America Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 546. North America Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 547. North America Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 548. North America Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 549. United States Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 550. United States Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 551. United States Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 552. United States Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 553. United States Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 554. United States Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 555. Canada Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 556. Canada Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 557. Canada Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 558. Canada Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 559. Canada Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 560. Canada Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 561. Mexico Azacitidine Drug, by Type USD Million (2021-2026)
  • Table 562. Mexico Azacitidine Drug, by Application USD Million (2021-2026)
  • Table 563. Mexico Azacitidine Drug, by Route of Administration USD Million (2021-2026)
  • Table 564. Mexico Azacitidine Drug, by Distribution Channel USD Million (2021-2026)
  • Table 565. Mexico Azacitidine Drug, by Dose USD Million (2021-2026)
  • Table 566. Mexico Azacitidine Drug, by End User USD Million (2021-2026)
  • Table 567. Azacitidine Drug Sales: by Type(Tonne)
  • Table 568. Azacitidine Drug Sales Acute myeloid leukemia (AML) , by Region Tonne (2021-2026)
  • Table 569. Azacitidine Drug Sales Myelodysplastic syndrome (MDS) , by Region Tonne (2021-2026)
  • Table 570. Azacitidine Drug Sales: by Application(Tonne)
  • Table 571. Azacitidine Drug Sales Refractory anemia (RA) , by Region Tonne (2021-2026)
  • Table 572. Azacitidine Drug Sales Refractory anemia with excess blasts (RAEB) , by Region Tonne (2021-2026)
  • Table 573. Azacitidine Drug Sales Chronic myelomonocytic leukemia (CMMoL) , by Region Tonne (2021-2026)
  • Table 574. Azacitidine Drug Sales Others , by Region Tonne (2021-2026)
  • Table 575. Azacitidine Drug Sales: by Route of Administration(Tonne)
  • Table 576. Azacitidine Drug Sales Oral , by Region Tonne (2021-2026)
  • Table 577. Azacitidine Drug Sales Injection , by Region Tonne (2021-2026)
  • Table 578. Azacitidine Drug Sales: by Distribution Channel(Tonne)
  • Table 579. Azacitidine Drug Sales Online , by Region Tonne (2021-2026)
  • Table 580. Azacitidine Drug Sales Offline , by Region Tonne (2021-2026)
  • Table 581. Azacitidine Drug Sales: by Dose(Tonne)
  • Table 582. Azacitidine Drug Sales 100 mg , by Region Tonne (2021-2026)
  • Table 583. Azacitidine Drug Sales 200 mg , by Region Tonne (2021-2026)
  • Table 584. Azacitidine Drug Sales 300 mg , by Region Tonne (2021-2026)
  • Table 585. Azacitidine Drug Sales Others , by Region Tonne (2021-2026)
  • Table 586. Azacitidine Drug Sales: by End User(Tonne)
  • Table 587. Azacitidine Drug Sales Hospital , by Region Tonne (2021-2026)
  • Table 588. Azacitidine Drug Sales Home Care Settings , by Region Tonne (2021-2026)
  • Table 589. Azacitidine Drug Sales Elderly Care Facilities , by Region Tonne (2021-2026)
  • Table 590. Azacitidine Drug Sales Others , by Region Tonne (2021-2026)
  • Table 591. South America Azacitidine Drug Sales, by Country Tonne (2021-2026)
  • Table 592. South America Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 593. South America Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 594. South America Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 595. South America Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 596. South America Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 597. South America Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 598. Brazil Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 599. Brazil Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 600. Brazil Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 601. Brazil Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 602. Brazil Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 603. Brazil Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 604. Argentina Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 605. Argentina Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 606. Argentina Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 607. Argentina Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 608. Argentina Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 609. Argentina Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 610. Rest of South America Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 611. Rest of South America Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 612. Rest of South America Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 613. Rest of South America Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 614. Rest of South America Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 615. Rest of South America Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 616. Asia Pacific Azacitidine Drug Sales, by Country Tonne (2021-2026)
  • Table 617. Asia Pacific Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 618. Asia Pacific Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 619. Asia Pacific Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 620. Asia Pacific Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 621. Asia Pacific Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 622. Asia Pacific Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 623. China Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 624. China Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 625. China Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 626. China Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 627. China Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 628. China Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 629. Japan Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 630. Japan Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 631. Japan Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 632. Japan Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 633. Japan Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 634. Japan Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 635. India Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 636. India Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 637. India Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 638. India Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 639. India Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 640. India Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 641. South Korea Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 642. South Korea Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 643. South Korea Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 644. South Korea Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 645. South Korea Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 646. South Korea Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 647. Taiwan Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 648. Taiwan Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 649. Taiwan Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 650. Taiwan Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 651. Taiwan Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 652. Taiwan Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 653. Australia Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 654. Australia Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 655. Australia Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 656. Australia Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 657. Australia Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 658. Australia Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 659. Rest of Asia-Pacific Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 660. Rest of Asia-Pacific Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 661. Rest of Asia-Pacific Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 662. Rest of Asia-Pacific Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 663. Rest of Asia-Pacific Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 664. Rest of Asia-Pacific Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 665. Europe Azacitidine Drug Sales, by Country Tonne (2021-2026)
  • Table 666. Europe Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 667. Europe Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 668. Europe Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 669. Europe Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 670. Europe Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 671. Europe Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 672. Germany Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 673. Germany Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 674. Germany Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 675. Germany Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 676. Germany Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 677. Germany Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 678. France Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 679. France Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 680. France Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 681. France Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 682. France Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 683. France Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 684. Italy Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 685. Italy Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 686. Italy Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 687. Italy Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 688. Italy Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 689. Italy Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 690. United Kingdom Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 691. United Kingdom Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 692. United Kingdom Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 693. United Kingdom Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 694. United Kingdom Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 695. United Kingdom Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 696. Netherlands Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 697. Netherlands Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 698. Netherlands Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 699. Netherlands Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 700. Netherlands Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 701. Netherlands Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 702. Rest of Europe Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 703. Rest of Europe Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 704. Rest of Europe Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 705. Rest of Europe Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 706. Rest of Europe Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 707. Rest of Europe Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 708. MEA Azacitidine Drug Sales, by Country Tonne (2021-2026)
  • Table 709. MEA Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 710. MEA Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 711. MEA Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 712. MEA Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 713. MEA Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 714. MEA Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 715. Middle East Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 716. Middle East Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 717. Middle East Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 718. Middle East Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 719. Middle East Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 720. Middle East Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 721. Africa Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 722. Africa Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 723. Africa Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 724. Africa Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 725. Africa Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 726. Africa Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 727. North America Azacitidine Drug Sales, by Country Tonne (2021-2026)
  • Table 728. North America Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 729. North America Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 730. North America Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 731. North America Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 732. North America Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 733. North America Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 734. United States Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 735. United States Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 736. United States Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 737. United States Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 738. United States Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 739. United States Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 740. Canada Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 741. Canada Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 742. Canada Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 743. Canada Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 744. Canada Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 745. Canada Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 746. Mexico Azacitidine Drug Sales, by Type Tonne (2021-2026)
  • Table 747. Mexico Azacitidine Drug Sales, by Application Tonne (2021-2026)
  • Table 748. Mexico Azacitidine Drug Sales, by Route of Administration Tonne (2021-2026)
  • Table 749. Mexico Azacitidine Drug Sales, by Distribution Channel Tonne (2021-2026)
  • Table 750. Mexico Azacitidine Drug Sales, by Dose Tonne (2021-2026)
  • Table 751. Mexico Azacitidine Drug Sales, by End User Tonne (2021-2026)
  • Table 752. Azacitidine Drug: by Type(USD/Units)
  • Table 753. Research Programs/Design for This Report
  • Table 754. Key Data Information from Secondary Sources
  • Table 755. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Azacitidine Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Azacitidine Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Azacitidine Drug: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Azacitidine Drug: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global Azacitidine Drug: by Dose USD Million (2015-2020)
  • Figure 9. Global Azacitidine Drug: by End User USD Million (2015-2020)
  • Figure 10. South America Azacitidine Drug Share (%), by Country
  • Figure 11. Asia Pacific Azacitidine Drug Share (%), by Country
  • Figure 12. Europe Azacitidine Drug Share (%), by Country
  • Figure 13. MEA Azacitidine Drug Share (%), by Country
  • Figure 14. North America Azacitidine Drug Share (%), by Country
  • Figure 15. Global Azacitidine Drug: by Type Tonne (2015-2020)
  • Figure 16. Global Azacitidine Drug: by Application Tonne (2015-2020)
  • Figure 17. Global Azacitidine Drug: by Route of Administration Tonne (2015-2020)
  • Figure 18. Global Azacitidine Drug: by Distribution Channel Tonne (2015-2020)
  • Figure 19. Global Azacitidine Drug: by Dose Tonne (2015-2020)
  • Figure 20. Global Azacitidine Drug: by End User Tonne (2015-2020)
  • Figure 21. South America Azacitidine Drug Share (%), by Country
  • Figure 22. Asia Pacific Azacitidine Drug Share (%), by Country
  • Figure 23. Europe Azacitidine Drug Share (%), by Country
  • Figure 24. MEA Azacitidine Drug Share (%), by Country
  • Figure 25. North America Azacitidine Drug Share (%), by Country
  • Figure 26. Global Azacitidine Drug: by Type USD/Units (2015-2020)
  • Figure 27. Global Azacitidine Drug share by Players 2020 (%)
  • Figure 28. Global Azacitidine Drug share by Players (Top 3) 2020(%)
  • Figure 29. Global Azacitidine Drug share by Players (Top 5) 2020(%)
  • Figure 30. BCG Matrix for key Companies
  • Figure 31. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 32. Celgene (United States) Revenue: by Geography 2020
  • Figure 33. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 35. Shilpa Medicare (United States) Revenue, Net Income and Gross profit
  • Figure 36. Shilpa Medicare (United States) Revenue: by Geography 2020
  • Figure 37. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 40. Teva Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 41. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 42. Sandoz (Germany) Revenue: by Geography 2020
  • Figure 43. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 44. Sanofi (France) Revenue: by Geography 2020
  • Figure 45. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 46. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 47. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 48. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 49. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 50. Dr. Reddy's Laboratories (India) Revenue: by Geography 2020
  • Figure 51. Global Azacitidine Drug: by Type USD Million (2021-2026)
  • Figure 52. Global Azacitidine Drug: by Application USD Million (2021-2026)
  • Figure 53. Global Azacitidine Drug: by Route of Administration USD Million (2021-2026)
  • Figure 54. Global Azacitidine Drug: by Distribution Channel USD Million (2021-2026)
  • Figure 55. Global Azacitidine Drug: by Dose USD Million (2021-2026)
  • Figure 56. Global Azacitidine Drug: by End User USD Million (2021-2026)
  • Figure 57. South America Azacitidine Drug Share (%), by Country
  • Figure 58. Asia Pacific Azacitidine Drug Share (%), by Country
  • Figure 59. Europe Azacitidine Drug Share (%), by Country
  • Figure 60. MEA Azacitidine Drug Share (%), by Country
  • Figure 61. North America Azacitidine Drug Share (%), by Country
  • Figure 62. Global Azacitidine Drug: by Type Tonne (2021-2026)
  • Figure 63. Global Azacitidine Drug: by Application Tonne (2021-2026)
  • Figure 64. Global Azacitidine Drug: by Route of Administration Tonne (2021-2026)
  • Figure 65. Global Azacitidine Drug: by Distribution Channel Tonne (2021-2026)
  • Figure 66. Global Azacitidine Drug: by Dose Tonne (2021-2026)
  • Figure 67. Global Azacitidine Drug: by End User Tonne (2021-2026)
  • Figure 68. South America Azacitidine Drug Share (%), by Country
  • Figure 69. Asia Pacific Azacitidine Drug Share (%), by Country
  • Figure 70. Europe Azacitidine Drug Share (%), by Country
  • Figure 71. MEA Azacitidine Drug Share (%), by Country
  • Figure 72. North America Azacitidine Drug Share (%), by Country
  • Figure 73. Global Azacitidine Drug: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Celgene (United States)
  • Mylan N.V. (United States)
  • Shilpa Medicare (United States)
  • Pfizer Inc. (United States)
  • Teva Pharmaceuticals (Israel)
  • Sandoz (Germany)
  • Sanofi (France)
  • GlaxoSmithKline (United Kingdom)
  • Novartis (Switzerland)
  • Dr. Reddy's Laboratories (India)
Additional players considered in the study are as follows:
Sun Pharmaceutical Industries Ltd. (India) , Natco Pharma (India) , Accord Healthcare (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation